Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMMX Immix Biopharma, Inc.

Pre-Market Trading 12-23 07:00:51 EST

2.17

-0.05

-2.25%

High2.32	Low2.09	Vol79.91K
Open2.22	D1 Closing2.22	Amplitude10.36%
Mkt Cap59.69M	Tradable Cap34.64M	Total Shares27.51M
T/O173.36K	T/O Rate0.50%	Tradable Shares15.96M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":2.17,"timestamp":1734728400000,"preClose":2.22,"halted":0,"volume":79910,"delay":0,"floatShares":15964753,"shares":27507637,"eps":-0.831087,"marketStatus":"Pre-Market Trading","change":-0.05,"latestTime":"12-23 07:00:51 EST","open":2.22,"high":2.32,"low":2.09,"amount":173358.312245,"amplitude":0.103604,"askPrice":2.33,"askSize":84,"bidPrice":2.08,"bidSize":73,"shortable":3,"etf":0,"ttmEps":-0.831087,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1734964200000},"marketStatusCode":1,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":2.17,"postHourTrading":{"tag":"盘后","latestPrice":2.17,"preClose":2.17,"latestTime":"19:37 EST","volume":10,"amount":20.9,"timestamp":1734741458876},"volumeRatio":0.34319468662424946,"impliedVol":0.0122,"impliedVolPercentile":0.013},"requestUrl":"/m/hq/s/IMMX/wiki","defaultTab":"wiki","newsList":[{"id":"2492102381","title":"BRIEF-Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients In Nexicart-2 U.S. Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492102381","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492102381?lang=en_us&edition=fundamental","pubTime":"2024-12-20 02:04","pubTimestamp":1734631447,"startTime":"0","endTime":"0","summary":"Dec 19 (Reuters) - Immix Biopharma Inc   :   * IMMIX BIOPHARMA ANNOUNCES POSITIVE U.S. CLINICAL DATA FROM FIRST FOUR PATIENTS IN NEXICART-2 U.S. TRIAL OF STERICALLY-OPTIMIZED CAR-T NXC-201 IN RELAPSED","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AL","IE00B19Z6F94.USD","IMMX","BK4104","IE0034390439.USD","BK4572"],"gpt_icon":0},{"id":"2492105706","title":"Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2492105706","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492105706?lang=en_us&edition=fundamental","pubTime":"2024-12-20 00:38","pubTimestamp":1734626328,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) on Thursday reported initial clinical data from the first four patients in its ongoing trial of NXC-201 CAR-T cell therapy for relapsed/refractory AL Amyloidosis.All four patien","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4230","IE0034390439.USD","BK4104","AL","BK4139","NXC","BK4572","CAR","BK4022","IE00B19Z6F94.USD","IMMX"],"gpt_icon":0},{"id":"2492317484","title":"Immix Biopharma announces data from four patients in NEXICART-2 U.S. trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492317484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492317484?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:40","pubTimestamp":1734619232,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced initial clinical data from the first four patients in the ongoing NEXICART-2U.S. study of sterically-optimized BCM...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-data-from-four-patients-in-nexicart-2-u-s-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-data-from-four-patients-in-nexicart-2-u-s-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2492179943","title":"Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in Nexicart-2 U.S. Trial of Sterically-Optimized CAR-T Nxc-201 in Relapsed/Refractory Light Chain (Al) Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2492179943","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492179943?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:35","pubTimestamp":1734618900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA8WQJTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2491697626","title":"Immix Biopharma announces publication of NXC-201 clinical results","url":"https://stock-news.laohu8.com/highlight/detail?id=2491697626","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491697626?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:55","pubTimestamp":1734360929,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced the Journal of Clinical Oncology published NXC-201 clinical results in relapsed/refractory AL Amyloidosis. The dat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-publication-of-nxc-201-clinical-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-publication-of-nxc-201-clinical-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NXC","IMMX"],"gpt_icon":0},{"id":"2490010284","title":"Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower","url":"https://stock-news.laohu8.com/highlight/detail?id=2490010284","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490010284?lang=en_us&edition=fundamental","pubTime":"2024-12-11 00:09","pubTimestamp":1733846988,"startTime":"0","endTime":"0","summary":"Immix Biopharma  said Tuesday that updated data for its drug NXC-201 showed a 94% overall response rate in patients with AL amyloidosis.The drug had a complete response rate of 75% in the phase 1b/2 Nexicart-1 study, according to the company.One patient maintained a complete response for 31.5 months, with ongoing remission as of Dec. 9, Immix added.Shares of Immix were down 7.4% in recent trading.Price: 2.25, Change: -0.29, Percent Change: -11.42","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2490192490","title":"Immix Biopharma Announces 75% Complete Response Rate (N=16); 31.5 Months Best Response Duration (Ongoing) for CAR-T Nxc-201 in Relapsed/Refractory Al Amyloidosis Patients at Ash 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490192490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490192490?lang=en_us&edition=fundamental","pubTime":"2024-12-10 22:39","pubTimestamp":1733841540,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA8BHSBF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2490094967","title":"Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094967","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094967?lang=en_us&edition=fundamental","pubTime":"2024-12-10 19:36","pubTimestamp":1733830619,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.So should Immix Biopharma  shareholders be worried about its cash burn?In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.Does Immix Biopharma Have A Long Cash Runway?How Is Immix Biopharma's Cash Burn Changing Over Time?Immix Biopharma has a market capitalisation of US$70m and burnt through US$16m last year, which is 24% of the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immix-biopharma-nasdaq-immx-spend-113659567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","LU2210149790.SGD","BK4139","IMMX","LU2210150020.SGD","MNQmain","QID","SQQQ","IE00B3QW5Z07.USD",".IXIC","NDAQ","IE00BGHQF748.EUR","NQmain","BK4588","PSQ","TQQQ","BK4112","IE00BKPKM429.USD","BK4585","QLD","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2483833899","title":"Immix Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483833899","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483833899?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:53","pubTimestamp":1731513231,"startTime":"0","endTime":"0","summary":"* Immix Biopharma Inc    reported a quarterly adjusted loss of 24 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -23 cents.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immix Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2481553152","title":"Immix Biopharma Inc    expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2481553152","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481553152?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:14","pubTimestamp":1731014098,"startTime":"0","endTime":"0","summary":"* Immix Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on November 9 (estimated) for the period ending September 30 2024   *    * LSEG's mean analyst est","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immix Biopharma Inc    expected to post a loss of 16 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2472696779","title":"Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2472696779","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472696779?lang=en_us&edition=fundamental","pubTime":"2024-10-03 19:07","pubTimestamp":1727953620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 03, 2024 07:07 ET (11:07 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2472525348","title":"Immix Biopharma Inc: NOW Dosing at Dose Expansion Level of 450 Mln Nxc-201 Car+T Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2472525348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472525348?lang=en_us&edition=fundamental","pubTime":"2024-10-02 21:32","pubTimestamp":1727875924,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241002:nFWN3LE179:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2472052588","title":"Immix Biopharma Advances CAR-T Nxc-201 to Expansion Cohort Dose Level in U.S. Al Amyloidosis Trial Nexicart-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2472052588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472052588?lang=en_us&edition=fundamental","pubTime":"2024-10-02 21:32","pubTimestamp":1727875924,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241002:nFWN3LE179:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2468572576","title":"Immix Biopharma Announces DR. Raymond Comenzo, Internationally Recognized Al Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2468572576","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468572576?lang=en_us&edition=fundamental","pubTime":"2024-09-19 21:31","pubTimestamp":1726752660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nTUA3HLM9G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2463255739","title":"Immix Biopharma Independent Director Acquires 2.6% More Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2463255739","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463255739?lang=en_us&edition=fundamental","pubTime":"2024-08-29 20:49","pubTimestamp":1724935741,"startTime":"0","endTime":"0","summary":"Even if it's not a huge purchase, we think it was good to see that Jason Hsu, the Independent Director of Immix Biopharma, Inc.  recently shelled out US$52k to buy stock, at US$2.23 per share. Although the purchase is not a big one, increasing their shareholding by only 2.6%, it can be interpreted as a good sign.In fact, the recent purchase by Independent Director Jason Hsu was not their only acquisition of Immix Biopharma shares this year. They previously made an even bigger purchase of US$267k worth of shares at a price of US$4.88 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price . Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a hi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immix-biopharma-independent-director-acquires-124901553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2462648164","title":"Immix Biopharma Expands US Nexicart-2 Trial for AL Amyloidosis With 3 Clinical Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2462648164","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462648164?lang=en_us&edition=fundamental","pubTime":"2024-08-28 22:30","pubTimestamp":1724855401,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) on Wednesday announced the inclusion of three more clinical trial sites in the US for its Nexicart-2 trial on relapsed/refractory AL amyloidosis.The newly added locations includ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4572","BK4139","IMMX","AL","IE0034390439.USD","BK4104","IE00B19Z6F94.USD"],"gpt_icon":0},{"id":"2462446377","title":"Immix Biopharma Expands U.S. Clinical Sites for Relapsed/Refractory Al Amyloidosis Trial Nexicart-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2462446377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462446377?lang=en_us&edition=fundamental","pubTime":"2024-08-28 21:32","pubTimestamp":1724851920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240828:nTUA6K1L2J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2460105747","title":"What Makes Immix Biopharma (IMMX) a New Buy Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2460105747","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460105747?lang=en_us&edition=fundamental","pubTime":"2024-08-20 00:00","pubTimestamp":1724083211,"startTime":"0","endTime":"0","summary":"Investors might want to bet on Immix Biopharma, Inc. , as it has been recently upgraded to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.As such, the Zacks rating upgrade for Immix Biopharma is essentially a positive comment on its earnings outlook that could have a favorable impact on ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/makes-immix-biopharma-immx-buy-160011065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2460035906","title":"Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2460035906","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460035906?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:42","pubTimestamp":1724071320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 19, 2024 08:42 ET (12:42 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2460236081","title":"Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2460236081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460236081?lang=en_us&edition=fundamental","pubTime":"2024-08-19 18:40","pubTimestamp":1724064021,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Equillium (EQ – Research Report), Foghorn Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-equillium-eq-foghorn-therapeutics-fhtx-and-immix-biopharma-inc-immx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-equillium-eq-foghorn-therapeutics-fhtx-and-immix-biopharma-inc-immx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","IMMX","BK4137","EQ","FHTX","BK4139","HCSG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":0.0637},{"period":"1month","weight":0.1923},{"period":"3month","weight":0.2056},{"period":"6month","weight":0.0637},{"period":"1year","weight":-0.6961},{"period":"ytd","weight":-0.6864}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.057386},{"month":2,"riseRate":0,"avgChangeRate":-0.196349},{"month":3,"riseRate":0,"avgChangeRate":-0.133286},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.121134},{"month":5,"riseRate":0.333333,"avgChangeRate":0.11363},{"month":6,"riseRate":0.666667,"avgChangeRate":0.161675},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.083428},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.078281},{"month":9,"riseRate":0.333333,"avgChangeRate":0.042748},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.044134},{"month":11,"riseRate":1,"avgChangeRate":0.313451},{"month":12,"riseRate":1,"avgChangeRate":0.425068}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc.","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immix Biopharma, Inc.,IMMX,Immix Biopharma, Inc.股票,Immix Biopharma, Inc.股票老虎,Immix Biopharma, Inc.股票老虎国际,Immix Biopharma, Inc.行情,Immix Biopharma, Inc.股票行情,Immix Biopharma, Inc.股价,Immix Biopharma, Inc.股市,Immix Biopharma, Inc.股票价格,Immix Biopharma, Inc.股票交易,Immix Biopharma, Inc.股票购买,Immix Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction